CA-VELODYNE-LIDAR
30.9.2020 15:33:11 CEST | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced shares of its common stock and warrants have begun trading on The Nasdaq Global Select Market under the ticker symbols “VLDR” (common stock) and “VLDRW” (warrants).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005166/en/
Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies, including revolutionary sensor and software solutions. These innovative technologies deliver performance, quality and flexibility to meet the needs of a wide range of industries such as autonomous vehicles and growing new markets. Currently, Velodyne serves the automotive industry with its broad product portfolio, providing lidar for high quality advanced driver assistance systems (ADAS) as well as for vehicle autonomy.
In addition to serving the automotive market, Velodyne is delivering lidar for new markets including smart city with smart intersections, security, mobile 3D mapping, industrial and factory robotics, smart agriculture, sidewalk delivery, drone/unmanned aerial vehicles (UAV) and more. There is a growing demand in these new markets as they ramp up business and expand. Velodyne’s lidar solutions are being utilized on a global scale by a highly diversified customer base. The company’s innovative Automated with Velodyne (AwV) program supports an integrator ecosystem to commercialize next-generation autonomous solutions using Velodyne lidar technology. Through the growing AwV program, Velodyne helps more than 65 companies by supporting innovation, promoting applications and creating lasting customer and business relationships.
Earlier this year, Velodyne named Dr. Anand Gopalan as its Chief Executive Officer. Previously serving as Velodyne’s Chief Technology Officer, Gopalan is a seasoned semiconductor executive with experience building and leading global technology companies.
“Today marks another great milestone for Velodyne, which started with the vision and ingenuity of our founder David Hall. We’ve grown into a global lidar powerhouse due to the significant contributions from our employees worldwide,” said Gopalan. “Becoming a public company enables Velodyne to invest more in delivering new transformative autonomous technology and powerful ADAS products to make our world a better place. With our broad portfolio of lidar sensors and revolutionary software, we strive to transform communities by advancing safer mobility for all.”
Jump-Starting the Autonomous Revolution
Hall invented real-time surround view lidar systems in 2005 to provide a precise vision system for autonomous vehicles competing in the DARPA Grand Challenge. Velodyne’s earliest customers, including Ford Motors, GM, Caterpillar and Google, met Hall at the DARPA Grand Challenge. Working closely with these customers, Hall continued innovate, harden and improve the original lidar design for 3D mapping and autonomous driving. Today, almost all major car makers working on safe autonomy have adapted Hall’s technology to spawn their autonomous vehicle programs, making the “autonomous revolution” possible. Other lidar companies emerged in the wake of Velodyne but have been challenged to surpass Velodyne Lidar in quality and brilliance of the original patented invention. One can today point to Hall as the instigator of the autonomous revolution which has the potential to change the direction of transportation and modern life.
The Intellectual Property Owners Education Foundation awarded Hall its 2018 Inventor of the Year award to recognize his many innovation accomplishments. In addition, the Alliance of Automobile Manufacturers (Auto Alliance) honored Hall as an Autos2050 award winner.
Velodyne is a leader in intellectual property for lidar technologies and holds an extensive portfolio of patents and patent applications. The company has served more than 300 customers in the automotive and technology industries, including nearly all the leading global automotive original equipment and technology manufacturers. Velodyne has received many industry awards for its achievements. Recent recognitions include Hardware Supplier of the Year in the 2020 TU-Automotive Awards and the prestigious 2019 Automotive News PACE Award.
Advancing Safer Mobility
Velodyne has a long-standing commitment to fostering understanding of the safety and mobility benefits of autonomous solutions to consumer, business, government, public safety and community audiences. The pinnacle of these efforts is Velodyne’s annual World Safety Summit on Autonomous Technology . The event has sparked collaborative work to advance solutions for rolling out autonomy and ADAS with the goal of safer mobility. Velodyne also partners with Mothers Against Drunk Driving and Partners for Automated Vehicle Education on public education about improving safety on roadways.
“Velodyne has the key technology that is enabling safer autonomous mobility,” said Hall. “Velodyne’s mission is to help save lives and move both people and goods more efficiently. We are also excited about the emergence of new markets as innovators discover new ways to use lidar. Today’s achievement of becoming a public company is a testament to our terrific team, our loyal customers, hard-working employees and invaluable investment partners as we ushered in a new vision and world with this technology.”
About Velodyne Lidar
Velodyne Lidar ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005166/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
